Providing value-driven pharmaceuticals in healthcare

Day One Wednesday 5th October 2011

Day One Wednesday 5th October 2011 »

Day Two Thursday 6th October 2011 »

last modified: 11 October '11

8am

Registration & refreshments

8.45am

Opening remarks from the chair

› Ed Schoonveld,

Principal, Author, The Price of Global Health, ZS Associates

THE US HEALTHCARE SYSTEM AND IT'S IMPACT ON MARKET ACCESS

9am

Healthcare funding: free market or Government crackdown?

The case for government interference (or not?)
What has been the experience globally?
What is appropriate and likely for the US?
Is the drug industry ready for tomorrow's needs?

› Ed Schoonveld,

Principal, Author, The Price of Global Health, ZS Associates

9.30am

Panel Discussion: US Healthcare policy reform – Its impact on market access and patient coverage

Updates on implementations

› Steve Phillips,

Director, Health Policy and Reimbursement, J&J

› Mary Grealy,

President, Healthcare Leadership Council

10.10am

The impact of the Independent Payment Advisory Board (IPAB) on market access and healthcare coverage

How will a spending budget system affect pharma?

› Chip Davis,

EVP, PhRMA

10.30am

Speed networking and morning refreshments

11am

Panel session: Strategies for managing growing Medicaid populations

Implications for the industry – including the need for chronic diseases treatments
Adoption of quality measures and health information technology (HIT) innovations

› Kelly Whitener,

Health Policy Advisor, Majority Staff/ Senator Max Baucus (D-Mont.), Senate Finance Committee

› Thomas L. Johnson,

Executive Director, MHPA

› Steve Phillips,

Director, Health Policy and Reimbursement, J&J

11.30am

State view on Health Reform’s Medicaid objectives

Medicaid and state budgets – the role of state insurance commissioners
Remembering that Medicaid is a state-run program and how cost control will be handled by state legislatures

› John J. Kaelin,

Senior Vice President, State Program Development, UnitedHealth Group Company

COMPARATIVE EFFECTIVENESS RESEARCH IN PRACTICE AND ITS IMPACT ON MARKET ACCESS

12pm

Evidence generation for Market Access

› Dean Hakanson,

VP & Head of Health Economics and Outcome Research, Novartis

12.20pm

Keynote session: Comparative Effectiveness Research: updates from the NIH Current thoughts and directions in NIH-funded CER

NIH perspectives on PCORI’s activities

› Dr Michael Lauer,

Director, Division of Cardiovascular Sciences, NIH

12.40pm

Use of CER by decision makers

What are the implications of US healthcare reform and the Patient-Centered Outcomes Research Institute for the CER?

› Eleanor Perfetto,

Senior Director, Reimbursement & Regulatory Affairs, Pfizer

1.10pm

Lunch

MEDICARE & REIMBURSEMENT INNVOVATION

2.10pm

Cost savings in Medicare and its impact on market access

Changing payment models and national health coverage; reimbursement for Medicare Part B products
Medicare advantage and part D prescription drug programs update

Panelists to be confirmed

2.40pm

Reimbursable innovation

Synchronizing regulatory, clinical & commercial strategies during product development to address the needs of stakeholers to achieve efficiency in the post-marketing setting

› Charles A. Stevens,

Vice President & General Manager, Reimbursement and Market Access, PAREXEL Consulting